Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India

We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthu, Valliappan, Agarwal, Ritesh, Rudramurthy, Shivaprakash Mandya, Thangaraju, Deepak, Shevkani, Manoj Radhakishan, Patel, Atul K., Shastri, Prakash Srinivas, Tayade, Ashwini, Bhandari, Sudhir, Gella, Vishwanath, Savio, Jayanthi, Madan, Surabhi, Hallur, Vinay Kumar, Maturu, Venkata Nagarjuna, Srinivasan, Arjun, Sethuraman, Nandini, Sibia, Raminder Pal Singh, Pujari, Sanjay, Mehta, Ravindra, Singhal, Tanu, Saxena, Puneet, Gupta, Varsha, Nagvekar, Vasant, Prayag, Parikshit, Patel, Dharmesh, Xess, Immaculata, Savaj, Pratik, Panda, Naresh, Rajagopal, Gayathri Devi, Parwani, Riya Sandeep, Patel, Kamlesh, Deshmukh, Anuradha, Vyas, Aruna, Sistla, Srinivas Kishore, Padaki, Priyadarshini A, Ramar, Dharshni, Sarkar, Saurav, Rachagulla, Bharani, Vallandaramam, Pattabhiraman, Premachandran, Krishna Prabha, Pawar, Sunil, Gugale, Piyush, Hosamani, Pradeep, Dutt, Sunil Narayan, Nair, Satish, Kalpakkam, Hariprasad, Badhwar, Sanjiv, Kompella, Kiran Kumar, Singla, Nidhi, Navlakhe, Milind, Prayag, Amrita, Singh, Gagandeep, Dhakecha, Poorvesh, Chakrabarti, Arunaloke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Synopsis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796192/
https://www.ncbi.nlm.nih.gov/pubmed/36573628
http://dx.doi.org/10.3201/eid2901.220926
Descripción
Sumario:We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.

Ejemplares similares